To comprehensively assess the pharmacological network of hesperetin, we examined its effects on mRNA levels of genes enriched in the top five-degree values in the PPI network and in the KEGG “non-alcoholic fatty liver” pathway (MYC, IL-6, IL1B, PTGS2, CYCS, TGFB1, CEBPA, DDIT3, and SOCS3) in FFA-induced HepG2 cells using qRT-PCR (Figure S1). The gene discussed is TGFB1; the disease is Hepatic steatosis.